Chromatography-Standardized Peanut Allergen Compositions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current allergen products for peanut allergy immunotherapy face challenges in providing reproducible and clinically relevant doses of key peanut allergens in their natural conformation, recognized by peanut-allergic patients, and ensuring consistent allergen potency across batches.
Innovation Solution
A method involving aqueous extraction followed by anion exchange chromatography and reverse phase chromatography to obtain peanut allergen compositions with controlled molar ratios of Ara h 1, Ara h 2, Ara h 3, and Ara h 6, minimizing high molecular mass aggregates, and ensuring accurate determination of monomeric allergen concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If aqueous extraction is used to obtain peanut allergen compositions, then the extraction process is simple and scalable, but the compositions contain high molecular mass aggregates that complicate dosing and reduce manufacturing precision
Solution Approach 1:
The patent segments the peanut allergen composition into monomeric forms through size exclusion chromatography, separating individual allergen molecules (Ara h 1, Ara h 2, Ara h 3, Ara h 6) from high molecular mass aggregates. This segmentation enables precise control over the molecular form of each allergen while maintaining the simplicity of the overall extraction process.
Solution Approach 2:
The patent changes the physical parameter of molecular size by using size exclusion chromatography to separate allergens based on their molecular weight. This parameter change allows the composition to be standardized in terms of monomeric allergen content, ensuring consistent dosing across batches while starting from a simple aqueous extraction process.
2Ease of manufacture
If conventional extraction methods are used, then the process is straightforward, but the allergen concentrations cannot be accurately determined due to presence of aggregates
Solution Approach 1:
The patent segments the complex extract into individual monomeric allergen species through size exclusion chromatography. This segmentation allows each allergen to be quantified independently using standardized assays, eliminating the interference of high molecular mass aggregates from the measurement process.
Solution Approach 2:
The patent introduces size exclusion chromatography as an intermediary step between the simple aqueous extraction and the final allergen quantification. This intermediary process separates and purifies the allergens, enabling accurate concentration determination while maintaining the simplicity of the initial extraction approach.
3Adaptability or versatility
If the composition treats a wide range of peanut allergic individuals with different sensitization patterns, then the therapeutic effectiveness increases, but the complexity of ensuring consistent dosing across different allergen combinations increases
Solution Approach 1:
The patent creates a universal allergen composition that contains standardized amounts of all four key peanut allergens (Ara h 1, Ara h 2, Ara h 3, Ara h 6) in monomeric form. This universal composition can treat patients with any combination of sensitization patterns, as the standardized dosing ensures consistent exposure to all relevant allergens regardless of individual sensitivity profile.
Solution Approach 2:
The patent standardizes the physical and chemical parameters of the allergen composition by controlling the molecular form (monomeric) and concentration of each allergen. This parameter standardization simplifies the dosing system, allowing a single standardized composition to effectively treat diverse patient populations with different sensitization patterns.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method allows for the production of compositions that can treat a wide range of peanut allergic individuals, inducing IgG4 antibodies and ensuring consistent allergen doses, independent of individual sensitization patterns, with reduced risk of anaphylactic reactions.
Implementation Method 1
subjecting said aqueous extract to anion exchange chromatography with stepwise or continuous aqueous salt gradient elution at pH in the range of 7 to 9
Implementation Method 2
reverse phase chromatography to obtain peanut allergen compositions with controlled molar ratios
Data Source
AI summary
Disclosed is compositions and pharmaceutically acceptable formulations comprising the four peanut allergens Ara h 1, Ara h 2, Ara h 3, and Ara h 6, as well as a kit comprising the compositions or pharmaceutically acceptable formulations, and methods of their preparation and their use in mitigation of peanut allergy and their uses in peanut allergen-specific immunotherapy.